tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Alterity Therapeutics Advances MSA Treatment with FDA Fast Track Designation

Story Highlights
  • Alterity Therapeutics received FDA Fast Track Designation for ATH434 to treat MSA.
  • Positive Phase 2 trial results for ATH434 highlight its potential in slowing MSA progression.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Alterity Therapeutics Advances MSA Treatment with FDA Fast Track Designation

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).

Alterity Therapeutics has received U.S. FDA Fast Track Designation for its investigational drug ATH434, aimed at treating Multiple System Atrophy (MSA), a neurodegenerative disease with no approved therapies. This designation, along with positive results from Phase 2 clinical trials, highlights the potential of ATH434 to slow disease progression and improve symptoms, reinforcing the company’s confidence in its MSA program as it prepares for further interactions with the FDA.

More about Alterity Therapeutics

Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. The company is actively engaged in creating innovative therapies to address unmet medical needs, particularly for conditions like Multiple System Atrophy (MSA).

YTD Price Performance: 60.0%

Average Trading Volume: 18,316,003

Technical Sentiment Signal: Sell

Current Market Cap: A$147.3M

See more data about ATH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1